Arecor has developed Arestat™, a formulation technology,
which enables the formulation of labile proteins and vaccines
as stable aqueous formulations even at high concentrations or
in the presence of ionising radiation.
As a simple reformulation, the technology can be readily
integrated into existing manufacturing processes. Arestat™
does not involve the covalent modification of biologics and uses
only GRAS (Generally Regarded As Safe) excipients approved by
relevant regulatory authorities.
Arecor is collaborating with a number of pharmaceutical and
biotech companies to develop recombinant proteins and vaccines
for application in drugs, medical devices or diagnostics.
Arestat™ has a proven track record and has been
incorporated into a Class III medical device (Oxyzyme™)
approved in the EU and Canada. It is currently being applied to
several recombinant biologics in various stages of development
for administration via parenteral, ocular and transdermal routes.